David T. Chao

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.

A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 07, 2023

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Journal: Immunotherapy advances

Published: August 17, 2022

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.

Journal: International journal of cancer

Published: May 21, 2020

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 21, 2019

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

Journal: Future oncology (London, England)

Published: March 12, 2019

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 17, 2018

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.

Journal: The Lancet. Oncology

Published: March 24, 2016

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 18, 2013

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: October 20, 2012

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 21, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026